HEALTHCARE REALTY TRUST INCORPORATED

HR

CIK 0001360604 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$286M
↓-7.6% -$23Mvs FY2024 (Q4)
Operating Income
$159M
↑+6.3% +$9Mvs FY2024 (Q4)
Net Income
$111M
↑+21.4% +$20Mvs FY2024 (Q4)
Gross Profit
$286M
↓-7.6% -$23Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
10/100
  • Profitability
    0ROIC 2.0% (10% = solid, 20%+ = moat)
  • Liquidity
    0Insufficient data
  • Leverage
    58D/E 0.85 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.12x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -7.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project HR's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

19%

Trailing 3-yr CAGR was 18.8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$34.79
Total enterprise IV
$12.17B
Diluted shares
0.35B
Terminal PV
$9.26B (76% of total)
Year-5 FCF
$1.09B
YearProjected FCFDiscounted PV
+1$544M$494M
+2$647M$535M
+3$770M$579M
+4$917M$626M
+5$1.09B$677M
Terminal$14.91B$9.26B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Dividends paid (TTM)
$387M
cash returned to holders
Stock buybacks (TTM)
$4M
share count reduction
Stock-based comp (TTM)
$22M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$9.21B
everything owned
Total liabilities
$4.53B
everything owed
Stockholders' equity
$4.62B
shareholder claim
Net debt
$3.89B
LT debt minus cash

Recent performance · 63 quarters

Revenue↓-7.6% -$23M
$286M
Net Income↑+37.9% +$35M
$-58M
Free Cash Flow↓-4.1% -$6M
$132M
Operating Margin↓-2.9pts
20.2%

Drill down